Crystallisation within transdermal rotigotine patch: Is there cause for concern?

Expert Opinion on Drug Delivery

Volumn 5, Issue 11, 2008, Pages 1169-1171

  Chaudhuri, K Ray ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ROTIGOTINE;

CRYOPRESERVATION; CRYSTALLIZATION; DRUG ABSORPTION; DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; EDITORIAL; HUMAN; PARKINSON DISEASE; RESTLESS LEGS SYNDROME; SHELF LIFE; THERMOSTABILITY; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANTIPARKINSON AGENTS; CRYSTALLIZATION; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 57049135288     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802500870     Document Type: Editorial

References (11)

1. Naidu Y, Chaudhuri KR. Rotigotine, a new transdermal patch for treatment of Parkinson's disease. Expert Opin Drug Deliv 2007;18:111-8
2. Rascol O. Transdermal delivery of dopmainergic agents. Neurology 2005;20:1502-7
3. Rotigotine (Neupro). Summary of product characteristics. UCB Pharma; April 2007
4. Mucke HA. Rotigotine. Schwarz Pharma. Drugs 2003;6:894-9
5. Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's Disease. Neurology 2005;659:S11-4
6. Poewe W, Rascol O, Quinn N, et al. Sp 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
7. Watts RL, Wendt RL, Nauseida B. Efficacy, safety and tolerability of the rotigotine patch in patients with early stage idiopathic Parkinson's disease: multicentre, multinational, randomized, double-blinded placebo-controlled trial. Mov Disord 2004;19:S258
8. Heindl M, Scheller D, Lebsanft K, et al. Continuous versus discontinuous administration of rotigotine in a rat model of dyskinesias. Parkinsonism Relat D 2005;11:PS002-6
9. Trenkwalder C, Benes H, Poewe W, et al. SP790 Study Group. Successful use of low-dose rotigotine in RLS: a randomised, placebo-controlled, double-blind, large-scale trial with rotigotine transdermal patch. Lancet Neurol 2008;7:595-604
10. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat D 2003;9:S3-9
11. Lewitt PA, Poewe W, Rascol O, et al. Overnight switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal patch. Eur J Neurol 2006;13(Suppl 2):321